Moscow, May 5, 2026 – PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces that the Board of Directors has approved a recommendation to the annual General Meeting of Shareholders on the amount of dividends for the 1st quarter of 2026.

The payout amount, according to the recommendation, may amount to 8.00 rubles per share, or 1.7 billion rubles, which corresponds to 46% of PROMOMED's adjusted net profit for 2025.

The issue of payment of dividends will be considered by the annual meeting of the General Meeting of Shareholders on 06/09/2026. The recommended date for determining the persons entitled to receive dividends is 06/20/2026.

The above amount of dividends was formed taking into account the currentThe dividend policy A company that provides for the payment of dividends based on the amount of adjusted net profit and the level of debt burden of the Group. Adjusted net profit is calculated as net profit for the period reduced by the amount of capitalized expenses on fixed assets and intangible assets and increased by the amount of depreciation on such capitalized expenses.

Although the payment is formally expected based on the results of the 1st quarter of 2026, in fact it was formed taking into account the results of the Group's activities for 2025 and calculated based on adjusted net profit for 2025. This approach is related to the specifics of the Group's holding structure, where PJSC PROMOMED is a holding company that does not operate. The Group's operational business is concentrated in subsidiaries, and the funds for the payment of dividends are transferred to the level of PJSC PROMOMED after the distribution of profits of the subsidiaries. Thus, the formal decision of the Board of Directors not to pay dividends based on the results of 2025 is purely technical in nature.

About the Company

PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market.

The company's structure includes its own world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Due to the use of its own chemical and biotechnological technologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

Statement of Limitation of liability

This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers to purchase any securities,
• as part of such offers or invitations,
• advertising of securities in the Russian Federation or other jurisdictions,
• an offer to purchase medicines,
• advertising of medicines,
• by encouraging or recommending transactions,
• and is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page: href="https://e-disclosure.ru/portal/company.aspx?id=38533">https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations, and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words, and expressions contained in this communication or related materials due to the influence of various external and internal factors.internal factors (general conditions of economic activity; risks related to the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.